| |
|
|
Session 4
Oral Abstract Presentations New Antiretrovirals Tuesday 10 am - 12:30 pm Auditorium |
| Moderators: | Hiroaki Mitsuya Kumamoto Univ Sch of Med, Japan and NCI, Bethesda, MD and Raymond Schinazi Emory Univ, VA Med Ctr, Atlanta, GA |
| 12:15 14lb | T-1249 Demonstrates Potent Antiviral Activity over 10 Day Dosing in Most Patients who Have Failed a Regimen Containing Enfuvirtide (ENF): Planned Interim Analysis of T1249-102, a Phase I/II Study GD Miralles*1, JP Lalezari2, N Bellos3, G Richmond4, Y Zhang1, H Murchison5, R Spence1, C Raskino6, RA DeMasi1 1Trimeris, Durham, NC, USA; 2Quest Clinical Research, San Francisco, CA, USA; 3Southwest Infectious Disease Associates, Dallas, TX, USA; 4Fort Lauderdale, FL, USA; 5Trimeris, Durham, NC USA; and 6Roche Products Ltd, Welwyn, U K |